A Phase 2 Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Unresectable Locally Advanced Or Metastatic Solid Tumors
  • Age: Between 55 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Have histologically-confirmed unresectable, locally advanced, or metastatic solid tumor with AXIN1 or APC mutations identified by sequencing tumor tissue (including primary tumor or metastases) or ctDNA. If a participant has colorectal cancer (CRC), then that participant must be RAS / RAF wild type
    2. Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type
    3. Aged 55 or older years

You may not be eligible for this study if the following are true:

    1. Received treatment with another mitogen-activated protein kinase (MEK) inhibitor within two months of first dose of REC-4881
    2. Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.